Versant Capital Management
MBX icon

Versant Capital Management’s MBX Biosciences MBX Stock Holding History

Versant Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.6K Buy
+180
New +$11.3K ﹤0.01% 2247
2026
Q2 		– Sell
-24
Closed -$716 – 2866
2026
Q1 		$716 Buy
+24
New +$816 ﹤0.01% 2690

Other funds holding MBX

Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Sowell Financial Services
Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return

Versant Capital Management's MBX Position: Q3 2026 in Review

Versant Capital Management opened a new position in MBX Biosciences (MBX) in Q3 2026: 180 shares worth $10.6K. The stake represents ﹤0.01% of the portfolio and ranks #2247 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in MBX as recently as Q1 2026.

Versant Capital Management first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold MBX as of Q3 2026.

  • Versant Capital Management held 180 shares of MBX Biosciences worth $10.6K as of Q3 2026.
  • MBX Biosciences was a new Versant Capital Management position in Q3 2026.
  • MBX Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2247 holding.
  • Versant Capital Management first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held MBX Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.